On September 19, Shandong Keyuan Pharmaceutical Co.,Ltd. (301281) announced that shareholder Wen Zehong has cumulatively reduced holdings by 2.7 million shares through centralized bidding and block trading, representing 2.50% of the company's total share capital. In the first half of 2025, Shandong Keyuan Pharmaceutical Co.,Ltd. achieved revenue of 228 million yuan and net profit attributable to the parent company of 42.68 million yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments